Bengbu Medical College

CELL WORLD - Aiming at Internationalization, Starting from Regulation - The 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration Successfully Held

Retrieved on: 
Monday, May 29, 2023
Laughter, European Medicines Agency, Tisagenlecleucel, First Affiliated Hospital of Xinjiang Medical University, Soochow University, Patient, Shanghai University, Cell, Medicines and Healthcare products Regulatory Agency, BLA, BioValley, DLBCL, Duke University School of Medicine, EMA, CELL, Anniversary Celebration, FDA, IND, Multimedia, China Institute for Innovation and Development Strategy, Therapy, MD Anderson Cancer Center, RMB, MHRA, Speech, CMC, Medication, Bristol Myers Squibb, Implementation, CDMO, Clinical trial, Novartis, IBLA International Competition, DoubleTree, Bengbu Medical College, Pharmaceutical industry, Medical device, EU, Medicine

SUZHOU, China, May 29, 2023 /PRNewswire/ -- On May 26, 2023, the "CELL WORLD 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration," meticulously planned by Hillgene Biopharma and Biovalley, was successfully held at the DoubleTree by Hilton in Wuzhong District, Suzhou.

Key Points: 
  • SUZHOU, China, May 29, 2023 /PRNewswire/ -- On May 26, 2023, the "CELL WORLD 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration," meticulously planned by Hillgene Biopharma and Biovalley, was successfully held at the DoubleTree by Hilton in Wuzhong District, Suzhou.
  • "This is the 1st summit of CELL WORLD, and Hillgene Biopharma will host this summit in the long term.
  • I hope this 1st CELL WORLD Global Cell Therapy Summit will further promote the development and innovation of cell therapy industry globally and provide more thoughts and practical examples."
  • The "CELL WORLD 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration" came to a perfect end amid the laughter and joy of the banquet.

Editas Medicine Appoints Baisong Mei, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Monday, July 18, 2022
Leadership, San Francisco, Patent, University, Biogen, Private Securities Litigation Reform Act, University of Toledo, Sickle cell disease, Patient, Wuhan University School of Medicine, File, CMC, Neurology, Nasdaq, University of California, San Francisco, Editas Medicine, U.S. Securities and Exchange Commission, Sirna, CRISPR, Beta thalassemia, GLOBE, Drug discovery, Bengbu Medical College, Harvard University, Hematology, BLA, Drug development, Haemophilia, Research centers and laboratories at the University of California, Berkeley, Company, Invention, Annual report, Partnership, Nephrology, Clinical trial, Pharmaceutical industry, Bayer, Sanofi, IND

CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the appointment of Baisong Mei, M.D., Ph.D., as the Companys Senior Vice President and Chief Medical Officer, effective immediately.

Key Points: 
  • CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the appointment of Baisong Mei, M.D., Ph.D., as the Companys Senior Vice President and Chief Medical Officer, effective immediately.
  • Editas Medicines blend of high-quality science, passion for developing transformative medicines, and urgency for helping patients attracted me to this role, and I am very excited to join the Editas team, said Baisong Mei, M.D., Ph.D., Chief Medical Officer, Editas Medicine.
  • Dr. Mei joins Editas Medicine from Sanofi, where he served as Senior Global Project Head in Rare Disease and Rare Blood Disorders.
  • Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.